Phase 1 dose escalation trial of the selective adenosine A2B antagonist PBF-1129 in patients with metastatic non-small cell lung cancer
Year: 2025
Type: article
Language: en
Topic: Adenosine and Purinergic Signaling
Authors and affiliations:
raw_author_name: Dwight H. Owen
raw_affiliation_strings: Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, 1800 Cannon Drive, 12th Floor, Columbus, OH, USA. Dwight.owen@osumc.edu
Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. Dwight.owen@osumc.edu
Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
raw_author_name: Ruohan Wu
raw_affiliation_strings: Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, 1800 Cannon Drive, 12th Floor, Columbus, OH, USA
raw_author_name: Lai Wei
raw_affiliation_strings: Center for Biostatistics, The Ohio State University Wexner Medical Center, Columbus, OH, USA
raw_author_name: Mikhail Dikov
raw_affiliation_strings: Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, 1800 Cannon Drive, 12th Floor, Columbus, OH, USA
raw_author_name: Shankar Suman
raw_affiliation_strings: Department of Oncology, Mayo Clinic, Rochester, MN, USA
Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, 1800 Cannon Drive, 12th Floor, Columbus, OH, USA
raw_author_name: Po-Lan Su
raw_affiliation_strings: Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Check Kung University, Tainan, Taiwan
Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, 1800 Cannon Drive, 12th Floor, Columbus, OH, USA
raw_author_name: Joseph Amann
raw_affiliation_strings: Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, 1800 Cannon Drive, 12th Floor, Columbus, OH, USA
raw_author_name: Shuxiao Guan
raw_affiliation_strings: Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, 1800 Cannon Drive, 12th Floor, Columbus, OH, USA
raw_author_name: Daniel Spakowicz
raw_affiliation_strings: Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, 1800 Cannon Drive, 12th Floor, Columbus, OH, USA
Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
raw_author_name: Catherine Schweitzer
raw_affiliation_strings: Clinical Trials Office, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
raw_author_name: Carly Pilcher
raw_affiliation_strings: Clinical Trials Office, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
raw_author_name: Michael B. Smith
raw_affiliation_strings: Department of Pharmacy, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
raw_author_name: Sarah Ferguson
raw_affiliation_strings: Clinical Trials Office, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
raw_author_name: Julio Castro Palomino
raw_affiliation_strings: Palobiofarma S.L., Pamplona, Spain
raw_author_name: Santiago Figueroa Pérez
raw_affiliation_strings: Palobiofarma S.L., Pamplona, Spain
raw_author_name: Erin M. Bertino
raw_affiliation_strings: Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, 1800 Cannon Drive, 12th Floor, Columbus, OH, USA
raw_author_name: Peter G. Shields
raw_affiliation_strings: Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, 1800 Cannon Drive, 12th Floor, Columbus, OH, USA
Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
raw_author_name: Kai He
raw_affiliation_strings: Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, 1800 Cannon Drive, 12th Floor, Columbus, OH, USA
Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
raw_author_name: Carolyn J. Presley
raw_affiliation_strings: Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, 1800 Cannon Drive, 12th Floor, Columbus, OH, USA
raw_author_name: Gregory A. Otterson
raw_affiliation_strings: Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, 1800 Cannon Drive, 12th Floor, Columbus, OH, USA
raw_author_name: William E. Carson
raw_affiliation_strings: Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, 1800 Cannon Drive, 12th Floor, Columbus, OH, USA
Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
raw_author_name: David P. Carbone
raw_affiliation_strings: Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, 1800 Cannon Drive, 12th Floor, Columbus, OH, USA
Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA